Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Alisertib - Takeda Oncology

Drug Profile

Alisertib - Takeda Oncology

Alternative Names: Alsertib; MLN-8237

Latest Information Update: 01 Oct 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Millennium Pharmaceuticals
  • Developer Fox Chase Cancer Center; Massachusetts General Hospital; Mayo Clinic; Millennium; National Cancer Institute (USA); Northwestern University; Ohio State University Comprehensive Cancer Center; Takeda Oncology; UNC Lineberger Comprehensive Cancer Center; University of Texas M. D. Anderson Cancer Center; Washington University School of Medicine; Weill Cornell Medical College; Yale University School of Medicine
  • Class 3-ring heterocyclic compounds; Antineoplastics; Azepines; Benzazepines; Benzoic acids; Fluorobenzenes; Phenyl ethers; Pyrimidines; Small molecules
  • Mechanism of Action Aurora kinase A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Acute myeloid leukaemia
  • Discontinued B-cell lymphoma; Brain cancer; Breast cancer; Burkitt's lymphoma; Cancer; Diffuse large B cell lymphoma; Follicular lymphoma; Gastric cancer; Gynaecological cancer; Head and neck cancer; Lymphoma; Mesothelioma; Myelodysplastic syndromes; Myelofibrosis; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Peripheral T-cell lymphoma; Prostate cancer; Small cell lung cancer; Solid tumours

Most Recent Events

  • 26 Jun 2019 Alisertib is still in phase II trials for Acute myeloid leukemia in USA (PO) (Takeda oncology pipeline 2019)
  • 27 Jul 2018 The Methodist Hospital System in collaboration with Millenium Pharmaceuticals withdraws a phase I trial prior to enrolment due to lack of funding for Solid tumours (Combination therapy, Second-line therapy of greater) and Lymphoma (Combination therapy, Second-line therapy of greater) in USA (PO) (NCT02780011)
  • 24 Jun 2018 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top